New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 22, 2014
09:54 EDTAGN, ACTAllergan drops after Watson files for generic Restasis
Shares of Allergan (AGN) after moving lower after the company disclosed this morning that it received a notice letter dated January 14, from Watson Laboratories (ACT) stating that Watson has filed an Abbreviated New Drug Application containing a “Paragraph IV” patent certification with the FDA seeking approval to market a generic version of the company’s Restasis. Allergan noted that on January 21, the United States Patent and Trademark Office issued a patent number covering a method of use relating to the Restasis product. On January 21, the company submitted the patent for listing in the Orange Book. The patent will expire in August 2024. Shares of Allergan are down 4%, or $4.49, to $115.58 in morning trading.
News For AGN;ACT From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
January 27, 2015
17:04 EDTACTShire granted petitiion by U.S. Supreme Court
Subscribe for More Information
January 26, 2015
17:34 EDTAGN, ACTActavis registration statement for Allergan acquisition declared effective
Subscribe for More Information
07:34 EDTACTActavis to acquire Auden Mckenzie for GBP306M accretive in FY15
Subscribe for More Information
January 22, 2015
05:57 EDTACTActavis, Valeant raise prospects of more healthcare deals, Financial Times says
Subscribe for More Information
January 21, 2015
12:30 EDTACT, AGNGlaxoSmithKline 'admired' by Pfizer CEO, FT reports
Subscribe for More Information
07:22 EDTACT, AGNActavis price target raised to $330 from $280 at Deutsche Bank
Subscribe for More Information
January 20, 2015
05:34 EDTACTActavis reports positive Phase III results for cariprazine
Gedeon Richter and Actavis announced positive results from a Phase III trial evaluating the efficacy and safety of cariprazine in the prevention of relapse in patients with schizophrenia. There were 101 patients randomized to cariprazine 3 to 9 mg per day and 99 randomized to placebo. The primary efficacy measure was time to first relapse during the double-blind period. There were 25 relapses in the cariprazine group versus 47 relapses in the placebo group. Treatment with cariprazine was associated with a 55% reduction in risk of relapse versus placebo.
January 14, 2015
18:18 EDTACTOn The Fly: After Hours Movers
Subscribe for More Information
16:59 EDTACTGalena, Orexo AB receive "Paragraph IV" patent certification notice from Actavis
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use